Charles Schwab Investment Management Inc Logic Bio Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$0.61 - $2.49 $7,013 - $28,630	-11,498 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$3.85 - $5.09 $44,267 - $58,524	11,498 New	11,498 $53,000
Q2 2021 Aug 16, 2021	SELL	$4.03 - $7.57 $163,803 - $307,690	-40,646 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$6.8 - $9.16 $43,846 - $59,063	6,448 Added 18.85%	40,646 $296,000
Q4 2020 Feb 16, 2021	BUY	$5.29 - $9.1 $43,790 - $75,329	8,278 Added 31.94%	34,198 $261,000
Q2 2020 Aug 14, 2020	BUY	$4.25 - $8.46 $32,941 - $65,573	7,751 Added 42.66%	25,920 $220,000
Q3 2019 Nov 08, 2019	SELL	$6.97 - $13.46 $30,075 - $58,079	-4,315 Reduced 19.19%	18,169 $197,000
Q2 2019 Aug 09, 2019	BUY	$9.77 - $17.08 $19,237 - $33,630	1,969 Added 9.6%	22,484 $293,000
Q1 2019 May 14, 2019	BUY	$7.93 - $10.41 $34,217 - $44,919	4,315 Added 26.64%	20,515 $203,000
Q4 2018 Feb 14, 2019	BUY	$7.88 - $17.98 $127,656 - $291,276	16,200 New	16,200 $169,000

Ticker LOGC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,962,700
Description
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.